Cullinan Therapeutics (CGEM) EBITDA Margin (2021)
Cullinan Therapeutics has reported EBITDA Margin over the past 1 years, most recently at 7.18% for Q1 2021.
- Quarterly results put EBITDA Margin at 7.18% for Q1 2021, changed N/A from a year ago — trailing twelve months through Dec 2021 was 346.94% (changed N/A YoY), and the annual figure for FY2021 was 350.56%, changed.
- EBITDA Margin for Q1 2021 was 7.18% at Cullinan Therapeutics.
- Over the last five years, EBITDA Margin for CGEM hit a ceiling of 7.18% in Q1 2021 and a floor of 7.18% in Q1 2021.